Concerns Raised About Patient-Reported Outcomes in CheckMate 214 Trial

An exploratory analysis showed that patients who received  nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up?
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news